Publications
Bone Regeneration
Sauter et al. 2026, bioRxiv (preprint)
Engineering autologous ossicles for the personalized modeling of acute myeloid leukemia
We show that OssiGel-derived autologous ossicles can be engineered directly from AML patient samples, establishing a patient-specific platform to study leukemic cell behavior and drug response. This work opens the door to personalized disease modeling and precision treatment testing built on our bone-graft technology.
Grigoryan et al. 2022, Sci. Transl. Med.
Engineering human mini-bones for the standardized modeling of healthy hematopoiesis, leukemia, and solid tumor metastasis
We demonstrated not only superior engraftment of human cord blood hematopoietic cells and primary acute myeloid leukemia samples, but also validated hOss as a metastatic site for breast cancer cells and neuroblastoma patient-derived xenograft cells. Collectively, our human mini-bones constitute a powerful preclinical platform to model bone-developing tumors using patient-derived material.
Dupard, Grigoryan et al. 2020, Trends Mol Med
Development of humanized ossicles: bridging the hematopoietic gap
Garcia Garcia et al. 2026, PNAS
Engineered and decellularized human cartilage graft exhibits intrinsic immunosuppressive properties and full skeletal repair capacity
We show that our engineered cartilage graft can be fully decellularized while retaining its capacity to guide complete bone repair, and that it carries intrinsic immunosuppressive properties that allow it to be used without patient matching. The graft successfully repaired critical-size bone defects in animal models, marking a key step toward a non-patient-specific, off-the-shelf therapy ready for clinical translation.
Prithiviraj, Garcia Garcia et al. 2025, eLife
Compositional editing of extracellular matrices by CRISPR/Cas9 engineering of human mesenchymal stem cell lines
We used CRISPR/Cas9 gene editing to customize the composition of our engineered cartilage grafts, targeting key regulators of bone formation. The resulting tissues retained their capacity to drive bone regeneration even after significant genetic modification, opening the door to tailoring graft composition and function for specific clinical needs.
Pigeot et al. 2021, Adv. Mater.
Manufacturing of human tissues as off-the-shelf grafts programmed to induce regeneration
Our study reported the engineering of human hypertrophic cartilage as an off-the-shelf material capable of inducing resident cells toward developmentally inspired processes, leading to de novo bone formation. The unprecedented, standardized osteoinductive performance, unmatched by commercially available materials or even living grafts, was critically dependent on a newly established, genetically engineered human cell line (MSOD-B).
Sauter et al. 2026, bioRxiv (preprint)
Engineering autologous ossicles for the personalized modeling of acute myeloid leukemia
Bone Marrow Modeling
We show that OssiGel-derived autologous ossicles can be engineered directly from AML patient samples, establishing a patient-specific platform to study leukemic cell behavior and drug response. This work opens the door to personalized disease modeling and precision treatment testing built on our bone-graft technology.
Grigoryan et al. 2022, Sci. Transl. Med.
Engineering human mini-bones for the standardized modeling of healthy hematopoiesis, leukemia, and solid tumor metastasis
Bone Marrow Modeling
We demonstrated not only superior engraftment of human cord blood hematopoietic cells and primary acute myeloid leukemia samples, but also validated hOss as a metastatic site for breast cancer cells and neuroblastoma patient-derived xenograft cells. Collectively, our human mini-bones constitute a powerful preclinical platform to model bone-developing tumors using patient-derived material.
Dupard, Grigoryan et al. 2020, Trends Mol Med
Development of humanized ossicles: bridging the hematopoietic gap
Bone Marrow Modeling
Garcia Garcia et al. 2026, PNAS
Engineered and decellularized human cartilage graft exhibits intrinsic immunosuppressive properties and full skeletal repair capacity
Bone Regeneration
We show that our engineered cartilage graft can be fully decellularized while retaining its capacity to guide complete bone repair, and that it carries intrinsic immunosuppressive properties that allow it to be used without patient matching. The graft successfully repaired critical-size bone defects in animal models, marking a key step toward a non-patient-specific, off-the-shelf therapy ready for clinical translation.
Prithiviraj, Garcia Garcia et al. 2025, eLife
Compositional editing of extracellular matrices by CRISPR/Cas9 engineering of human mesenchymal stem cell lines
Bone Regeneration
We used CRISPR/Cas9 gene editing to customize the composition of our engineered cartilage grafts, targeting key regulators of bone formation. The resulting tissues retained their capacity to drive bone regeneration even after significant genetic modification, opening the door to tailoring graft composition and function for specific clinical needs.
Pigeot et al. 2021, Adv. Mater.
Manufacturing of human tissues as off-the-shelf grafts programmed to induce regeneration
Bone Regeneration
Our study reported the engineering of human hypertrophic cartilage as an off-the-shelf material capable of inducing resident cells toward developmentally inspired processes, leading to de novo bone formation. The unprecedented, standardized osteoinductive performance, unmatched by commercially available materials or even living grafts, was critically dependent on a newly established, genetically engineered human cell line (MSOD-B).
Publications
Bone Marrow Modeling
Engineering autologous ossicles for the personalized modeling of acute myeloid leukemia
Sauter et al. 2026, bioRxiv (preprint)
We show that OssiGel-derived autologous ossicles can be engineered directly from AML patient samples, establishing a patient-specific platform to study leukemic cell behavior and drug response. This work opens the door to personalized disease modeling and precision treatment testing built on our bone-graft technology.
Bone Marrow Modeling
Engineering human mini-bones for the standardized modeling of healthy hematopoiesis, leukemia, and solid tumor metastasis
Grigoryan et al. 2022, Sci. Transl. Med.
We demonstrated not only superior engraftment of human cord blood hematopoietic cells and primary acute myeloid leukemia samples, but also validated hOss as a metastatic site for breast cancer cells and neuroblastoma patient-derived xenograft cells. Collectively, our human mini-bones constitute a powerful preclinical platform to model bone-developing tumors using patient-derived material.
Bone Marrow Modeling
Development of humanized ossicles: bridging the hematopoietic gap
Dupard, Grigoryan et al. 2020, Trends Mol Med
In this review, we described the specificities of the hOss models and highlighted their potential and limitations. Ultimately, we proposed directions for the development of hOss as a technological platform for human hematopoietic studies.
Bone Regeneration
Engineered and decellularized human cartilage graft exhibits intrinsic immunosuppressive properties and full skeletal repair capacity
Garcia Garcia et al. 2026, PNAS
We show that our engineered cartilage graft can be fully decellularized while retaining its capacity to guide complete bone repair, and that it carries intrinsic immunosuppressive properties that allow it to be used without patient matching. The graft successfully repaired critical-size bone defects in animal models, marking a key step toward a non-patient-specific, off-the-shelf therapy ready for clinical translation.
Bone Regeneration
Compositional editing of extracellular matrices by CRISPR/Cas9 engineering of human mesenchymal stem cell lines
Prithiviraj, Garcia Garcia et al. 2025, eLife
We used CRISPR/Cas9 gene editing to customize the composition of our engineered cartilage grafts, targeting key regulators of bone formation. The resulting tissues retained their capacity to drive bone regeneration even after significant genetic modification, opening the door to tailoring graft composition and function for specific clinical needs.
Bone Regeneration
Manufacturing of human tissues as off-the-shelf grafts programmed to induce regeneration
Pigeot et al. 2021, Adv. Mater.
Our study reported the engineering of human hypertrophic cartilage as an off-the-shelf material capable of inducing resident cells toward developmentally inspired processes, leading to de novo bone formation. The unprecedented, standardized osteoinductive performance, unmatched by commercially available materials or even living grafts, was critically dependent on a newly established, genetically engineered human cell line (MSOD-B).
Publications
Sauter et al. 2026, bioRxiv (preprint)
Engineering autologous ossicles for the personalized modeling of acute myeloid leukemia
We show that OssiGel-derived autologous ossicles can be engineered directly from AML patient samples, establishing a patient-specific platform to study leukemic cell behavior and drug response. This work opens the door to personalized disease modeling and precision treatment testing built on our bone-graft technology.
Sauter et al. 2026, bioRxiv (preprint)
Engineering autologous ossicles for the personalized modeling of acute myeloid leukemia
We show that OssiGel-derived autologous ossicles can be engineered directly from AML patient samples, establishing a patient-specific platform to study leukemic cell behavior and drug response. This work opens the door to personalized disease modeling and precision treatment testing built on our bone-graft technology.
Sauter et al. 2026, bioRxiv (preprint)
Engineering autologous ossicles for the personalized modeling of acute myeloid leukemia
We show that OssiGel-derived autologous ossicles can be engineered directly from AML patient samples, establishing a patient-specific platform to study leukemic cell behavior and drug response. This work opens the door to personalized disease modeling and precision treatment testing built on our bone-graft technology.
Sauter et al. 2026, bioRxiv (preprint)
Engineering autologous ossicles for the personalized modeling of acute myeloid leukemia
We show that OssiGel-derived autologous ossicles can be engineered directly from AML patient samples, establishing a patient-specific platform to study leukemic cell behavior and drug response. This work opens the door to personalized disease modeling and precision treatment testing built on our bone-graft technology.
Sauter et al. 2026, bioRxiv (preprint)
Engineering autologous ossicles for the personalized modeling of acute myeloid leukemia
We show that OssiGel-derived autologous ossicles can be engineered directly from AML patient samples, establishing a patient-specific platform to study leukemic cell behavior and drug response. This work opens the door to personalized disease modeling and precision treatment testing built on our bone-graft technology.
Sauter et al. 2026, bioRxiv (preprint)
Engineering autologous ossicles for the personalized modeling of acute myeloid leukemia
We show that OssiGel-derived autologous ossicles can be engineered directly from AML patient samples, establishing a patient-specific platform to study leukemic cell behavior and drug response. This work opens the door to personalized disease modeling and precision treatment testing built on our bone-graft technology.